Image
Recommendation
Adjuvant chemotherapy – Indications #1
Consider adjuvant chemotherapy for all patients with breast cancer whose disease is at high risk of recurrence and has a subtype likely to respond to adjuvant chemotherapy (e.g. triple negative; HER2-postive; luminal B).
Adjuvant chemotherapy should be considered for all patients with early breast cancer whose disease is at moderate/high risk of recurrence
At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated a 1+, directly applicable to the target population, and demonstrating overall consistency of results
How this guidance was developed
This recommendation was adapted from the NCCP 2015 guidelines (Ireland). The source recommendation was based on a systematic review of the evidence conducted to September 2014 and was graded 'A' (using SIGN methods) by the source guideline authors. The source recommendation was adapted to remove reference to ‘moderate risk of recurrence’ as the evidence in favour of chemotherapy in this group of patients is not as clear as for patients with a high risk of recurrence. Reference to the likely responsiveness of the cancer based on its biology was also added.
Adjuvant chemotherapy – Indications #1
Recommendation
Consider adjuvant chemotherapy for all patients with breast cancer whose disease is at high risk of recurrence and has a subtype likely to respond to adjuvant chemotherapy (e.g. triple negative; HER2-postive; luminal B).
Principles in action
Patient-centred care
Image
Safe and quality care
Image
Communication
This recommendation was adapted from the NCCP 2015 guidelines (Ireland). The source recommendation was based on a systematic review of the evidence conducted to September 2014 and was graded 'A' (using SIGN methods) by the source guideline authors. The source recommendation was adapted to remove reference to ‘moderate risk of recurrence’ as the evidence in favour of chemotherapy in this group of patients is not as clear as for patients with a high risk of recurrence. Reference to the likely responsiveness of the cancer based on its biology was also added.